Our Focus is Immuno-Oncology
Since we began research and drug discovery in hematological cancers, we have made seminal inventions and established proprietary know how in the following areas:
- novel serum B-cell marker for multiple myeloma and possibly other cancers and diseases
- pharmaceutical method to potentiate the efficacy of multiple myeloma BiTE and ADC therapies targeting a particular B-cell surface antigen
- combination of approved drugs that has demonstrated a 50% response rate in a multiple myeloma pilot study
- pharmaceutical therapy that enhances T-cell activity by reducing checkpoint protein expression
- PDX animal models in multiple myeloma
Our sBCMA Test monitors and predicts outcomes for multiple myeloma and chronic lymphocytic leukemia patients. In many ways, it is similar to the PSA test for prostate cancer. The assay is based on measuring B-cell maturation antigen (BCMA), which is shed from the surface of B-cells.
The advantage of our new peripheral blood test is it can more rapidly and accurately assess changes in a patient’s cancer. We believe it can further predict treatment efficacy. To date, we have tested the BCMA Test in over 1,000 multiple myeloma and chronic lymphocytic leukemia patient samples. We now offer the sBCMA Test under GLP conditions for clinical trial samples.
Our patient-derived xenograph (PDX) animal models are derived from fresh multiple myeloma tumor samples, not cell lines. We are completely unique in this capability and believe they are most informative of candidate drug efficacy. We can test your candidate drug in our multiple myeloma PDX animal models.
We have an exceptional team of drug discovery and development scientists that closely collaborate with a large cancer center, drug discovery institute, and clinical trials organization. To date, we have completed a license to one of our CAR-T technologies with Juno Therapeutics, now owned by Celgene.
We continue to build upon our intellectual property by testing our B-cell biomarker in hematological cancers beyond multiple myeloma, solid tumors, immunodeficiency, and transplant rejection.
OncoTracker Signs Licensing